Shah Capital nominates two highly qualified independent director candidates for Novavax
RALEIGH, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax (NASDAQ: NVAX), has today issued the below statement:
- These include colossal marketing failures, a non-existent partnership strategy, no clear understanding of technology, questionable regulatory management, and ongoing operating losses and inefficiencies.
- “It is the view of Shah Capital therefore that Novavax must urgently adopt a more innovative and dynamic sales and marketing strategy.
- Furthermore, Novavax should turn its Matrix-M adjuvant franchise’s inactive pipeline candidates (such as Flu, RSV, and H5N1) into active opportunities through outside capital infusion.
- “It is for these reasons outlined above that Shah Capital is calling for an end to the historic mismanagement of this business.